# US 2010/0166848 A1 · Liposomal formulations for treating cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0166848 A1
- Document ID: US20100166848A1
- Status: Published application
- Kind: A1
- Application number: 12/676,013
- Filed: 2008-09-11
- Published: 2010-07-01
- Earliest claimed: 2007-09-11
- Inventors: Joseph Ciccolini; Raphaelle Fanciullino
- Web page: https://patentgrep.com/patent/US20100166848A1

## CPC

- A61K 9/127: Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K 9/00: Medicinal preparations characterised by special physical form {(nuclear magnetic resonance contrast preparations or magnetic resonance imaging contrast preparations A61K49/18; preparations containing radioactive substances A61K51/12)}
- A61K 9/1277: Preparation processes; Proliposomes
- A61K 9/1278: Post-loading, e.g. by ion or pH gradient
- A61K 31/513: having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K 31/7076: containing purines, e.g. adenosine, adenylic acid
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- A61K 2300/00: Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention provides a pharmaceutical composition comprising liposomes which coencapsulate 5-fluorouracil (5-FU) and 2′-deoxyinosine (d-Ino). In a preferred embodiment, the liposomes comprise phosphatidylcholine (PC), phosphatidyl-glycol (PG) and sterol, preferably in a molar ratio PC/PG/sterol of 20-80/10-60/15-60. The invention further provides a method for preparing liposomes which coencapsulate 5-fluorouracil (5-FU) and 2′-deoxyinosine (d-Ino), and the use thereof for the manufacture of a medicament for treating cancer in a patient.

## Claims

### Claim 1

A pharmaceutical composition comprising liposomes which coencapsulate 5-fluorouracil (5-FU) and 2′-deoxyinosine (d-Ino).

### Claim 2 (depends on 1)

The pharmaceutical composition of claim 1, wherein the liposomes comprise phosphatidylcholine (PC), phosphatidylglycol (PG) and sterol.

### Claim 3 (depends on 2)

The pharmaceutical composition of claim 2, wherein the liposomes comprise phosphatidylcholine (PC), phosphatidylglycol (PG) and sterol in a molar ratio PC/PG/sterol of 20-80/10-60/15-60.

### Claim 4 (depends on 3)

The composition of claim 3, wherein the liposomes comprise a molar ratio PC/PG/sterol of 30-50/20-30/20-40.

### Claim 5 (depends on 4)

The composition of claim 4, wherein the liposomes comprise a molar ratio PC/PG/sterol of 35-45/24-28/24-38.

### Claim 6 (depends on 2)

The composition of claim 2, wherein the sterol is cholesterol.

### Claim 7 (depends on 2)

The composition of claim 2, further comprising polyethylene glycol (PEG) out of the liposome membrane.

### Claim 8 (depends on 7)

The composition of claim 7, wherein the liposomes comprise phosphatidylcholine (PC), phosphatidylglycol (PG), sterol and PEG in a molar ratio PC/PG/sterol/PEG of 20-80/10-60/15-60/0.30-1.5.

### Claim 9 (depends on 8)

The composition of claim 8, wherein the liposomes comprise a molar ratio of PC/PG/cholesterol/PEG of about 40/26/33/0.68.

### Claim 10 (depends on 1)

The composition of claim 1, wherein the liposomes have a mean diameter of between 50 and 200 nm.

### Claim 11 (depends on 1)

The composition of claim 1, wherein the liposomes further encapsulate folinic acid.

### Claim 12

A method for preparing liposomes which coencapsulate 5-fluorouracil (5-FU) and 2′-deoxyinosine (d-Ino), which method comprises the steps consisting of
(a) dissolving a lipid mixture comprising phosphatidylcholine (PC), phosphatidylglycol (PG) and sterol in an alcoholic solvent, and removing the solvent to form a lipid film;
(b) hydrating the lipid film with a solution containing 5-fluorouracil and 2′-deoxyinosine, to form a lipid dispersion;
(c) forming Multilamellar vesicles (MLVs) by mixing the lipid dispersion;
(d) obtaining Small unilamellar vesicles (SUVs) therefrom, by sonication.

### Claim 13 (depends on 12)

The method of claim 12, wherein the solution of step (b) further comprises folinic acid, whereby liposomes which coencapsulate 5-FU, d-Ino, and folinic acid, are prepared.

### Claim 14 (depends on 12)

Liposomes obtainable by the method of claim 12.

### Claim 15

A method for treating cancer in a patient, which method comprises administering an effective amount of a pharmaceutical composition comprising liposomes which coencapsulate 5-fluorouracil (5-FU) and 2′-deoxyinosine (d-Ino) in a patient in need thereof.

### Claim 16 (depends on 15)

The method of claim 15, wherein the patient has shown chemoresistance to 5-FU or to another fluoropyrimidine drug.

### Claim 17 (depends on 3)

The composition of claim 3, wherein the sterol is cholesterol.

### Claim 18 (depends on 4)

The composition of claim 4, wherein the sterol is cholesterol.

### Claim 19 (depends on 5)

The composition of claim 5, wherein the sterol is cholesterol.

### Claim 20 (depends on 3)

The composition of claim 3, further comprising polyethylene glycol (PEG) out of the liposome membrane.
